Global Parkinson’s Disease Drugs Market to Reach $10 Billion by 2030
The global market for Parkinson’s Disease Drugs estimated at US$6 Billion in the year 2022, is projected to reach a revised size of US$10 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2022-2030. Oral, one of the segments analyzed in the report, is projected to record 7.6% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Injection segment is readjusted to a revised 6.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 11.9% CAGR
The Parkinson’s Disease Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.Select Competitors (Total 43 Featured) -
- AbbVie Inc.
- ACADIA Pharmaceuticals
- Boehringer Ingelheim GmbH
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Impax Laboratories Inc.
- M Somerset Pharmaceuticals Inc.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Orion Pharma
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd
- Vertical Pharmaceuticals
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- ACADIA Pharmaceuticals
- Boehringer Ingelheim GmbH
- GlaxoSmithKline PLC
- H. Lundbeck A/S
- Impax Laboratories Inc.
- M Somerset Pharmaceuticals Inc.
- Merck & Co. Inc.
- Mylan NV
- Novartis International AG
- Orion Pharma
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd
- Vertical Pharmaceuticals
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 94 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 6 Billion |
Forecasted Market Value ( USD | $ 10 Billion |
Compound Annual Growth Rate | 6.6% |
Regions Covered | Global |